#United Kingdom #Oxford #Infinitopes #Dan Menichella #Jo Brewer

Infinitopes Strengthens Leadership with Biotech Innovators

Infinitopes, an emerging leader in precision immuno-oncology, has made significant strides towards enhancing its governance and accelerating its clinical initiatives by welcoming two esteemed professionals to its Board as Non-Executive Directors. Dan Menichella and Dr. Jo Brewer bring extensive expertise in biotechnology and cancer therapeutics, poised to steer the company into its next phase of growth as it prepares to launch clinical trials for its pioneering vaccine, ITOP1, aimed at combating oesophageal cancer.

New Board Members' Profiles

Dan Menichella

Dan Menichella's illustrious career in biotechnology is marked by a wealth of experience in vaccine development and corporate strategy. Previously, as the CEO of CureVac's U.S. subsidiary, he facilitated groundbreaking collaborations, including a notable $1.7 billion partnership with Eli Lilly for cancer vaccines. Under Menichella's leadership, CureVac AG grew significantly, reflecting his unmatched track record in driving biotech success. His strategic insights and networking prowess are set to significantly benefit Infinitopes as the company embarks on its clinical trials. Menichella expressed his enthusiasm for joining Infinitopes, citing the company’s innovative spirit and its commitment to transforming cancer treatment paradigms.

Dr. Jo Brewer

A distinguished figure in cancer immunotherapy, Dr. Jo Brewer has spent over two decades steering advanced therapies from conception to clinical application. Currently, she serves as Chief Scientific Officer at Adaptimmune, where she has played a pivotal role in bringing the first engineered T-cell therapy for solid tumors to the market. Brewer’s deep understanding of T-cell therapies and her substantial contributions at Adaptimmune will be invaluable as Infinitopes aims to navigate the complexities of clinical development. She recognizes the potential for Infinitopes' AI-driven Immunomics™ platform to reshape cancer treatment landscapes and is excited to contribute her expertise at this critical juncture.

The Vision for ITOP1

Infinitopes is on the cusp of a major milestone as it gears up for Phase I/IIa clinical trials of its lead vaccine candidate, ITOP1. This vaccine is being developed with the promise of preventing the recurrence of oesophageal cancer, an area where there is a critical need for innovative solutions. The upcoming trials will be conducted across four NHS university cancer centers in the UK, demonstrating a strong commitment to integrating advanced therapeutic approaches into real-world clinical practices.

Funding and Innovative Platforms

Earlier in 2024, the company secured an impressive £12.8 million in seed funding, underscoring market confidence in its AI-driven Precision Immunomics™ technology. This proprietary platform is engineered to design highly effective and safe therapeutics tailored for various cancer types. With a dedicated team that has expanded rapidly from three founding members to 28 skilled professionals, Infinitopes is making remarkable progress in establishing itself as a key player in the cancer biotechnology sector.

While the challenges in biotechnology and clinical trials are significant, the leadership of Menichella and Brewer, along with Infinitopes’ robust scientific advisory board, positions the company favorably for future successes. The blend of strategic foresight, scientific innovation, and a passionate commitment to patient care forms the backbone of Infinitopes’ mission to redefine outcomes for cancer patients worldwide.

As Infinitopes continues to grow, the combined insights from its new board members will undoubtedly catalyze advancements in cancer immunotherapy and align the company with its vision to deliver transformative treatments for patients in need.